Revance Therapeutics (NASDAQ:RVNC) Upgraded at ValuEngine

ValuEngine upgraded shares of Revance Therapeutics (NASDAQ:RVNC) from a sell rating to a hold rating in a research note issued to investors on Thursday morning, ValuEngine reports.

Other research analysts also recently issued reports about the stock. BidaskClub upgraded shares of Revance Therapeutics from a sell rating to a hold rating in a report on Wednesday. Barclays began coverage on shares of Revance Therapeutics in a report on Tuesday, June 11th. They set an overweight rating and a $28.00 price target for the company. Finally, Mizuho reiterated a buy rating and set a $37.00 price target on shares of Revance Therapeutics in a report on Wednesday, April 24th. Five equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock has an average rating of Buy and an average price target of $33.09.

RVNC stock traded down $0.29 during trading on Thursday, reaching $12.27. 298,600 shares of the company were exchanged, compared to its average volume of 431,539. The business’s 50-day moving average is $12.23. The company has a market capitalization of $555.80 million, a P/E ratio of -3.11 and a beta of 1.02. Revance Therapeutics has a twelve month low of $10.37 and a twelve month high of $29.90. The company has a debt-to-equity ratio of 0.13, a current ratio of 8.13 and a quick ratio of 8.13.

Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.83) by ($0.02). The company had revenue of $0.28 million for the quarter, compared to analyst estimates of $1.85 million. Revance Therapeutics had a negative return on equity of 75.31% and a negative net margin of 3,745.97%. As a group, research analysts forecast that Revance Therapeutics will post -3.63 earnings per share for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the company. FNY Investment Advisers LLC acquired a new position in Revance Therapeutics in the 2nd quarter valued at approximately $37,000. Edge Wealth Management LLC increased its position in Revance Therapeutics by 550.0% in the 1st quarter. Edge Wealth Management LLC now owns 3,250 shares of the biopharmaceutical company’s stock valued at $51,000 after acquiring an additional 2,750 shares during the period. BNP Paribas Arbitrage SA acquired a new position in Revance Therapeutics in the 1st quarter valued at approximately $125,000. Legal & General Group Plc increased its position in Revance Therapeutics by 21.7% in the 4th quarter. Legal & General Group Plc now owns 6,445 shares of the biopharmaceutical company’s stock valued at $130,000 after acquiring an additional 1,150 shares during the period. Finally, Campbell & CO Investment Adviser LLC acquired a new position in Revance Therapeutics in the 1st quarter valued at approximately $170,000. 94.86% of the stock is owned by institutional investors.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which is in phase III clinical trials to treat glabellar (frown) lines and cervical dystonia; and in phase II clinical trials for the treatment of plantar fasciitis, adult upper limb spasticity, and chronic migraine.

Read More: Moving Average Convergence Divergence (MACD)

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.